To counter that notion, a committee was formed to make modifications that would help enhance compound's viability.
To exclude toxic effects of the compound, cell viability was determined by trypan blue (Gibco/Invitrogen).
We tested the effect of the R2 compound on viability of the MCF-7 breast cancer cell line with wild type p53.
The R2 compound decreased viability and clonogenicity of HCT116 cells in a p53-dependent manner, and reactivated FAK-inhibited transcriptional activity of p53 with p21, Mdm-2 and Bax transcriptional targets.
In MCF-7 breast cancer cells, with little constitutively active Akt, d-3-deoxy-diC8PI (but not l-compounds) decreases viability concomitant with increased cleavage of PARP and caspase 9, indicative of apoptosis.
Thirty six hours after the addition of test compounds, cell viability was measured by the MTS assay.
Similar to U2OS, only 48 compounds diminished viability at ≥20 μM.
Therefore, NCI-H1650 cells were chosen for further studies of the effects of these compounds on viability and colony formation.
Usually, compounds decrease viability to greater extent after longer than after shorter exposure times (e.g., [ 17, 18]).
The effect of each of the compounds on viability in a particular cell line, was estimated by comparing luminescence readings from drug-treated cells with those from cells treated with the compound vehicle, DMSO.
